Distinguishing features of primary hyperparathyroidism in patients with breast cancer

✍ Scribed by Deborah M. Axelrod; Richard S. Bockman; George Y. Wong; Michael P. Osborne; David W. Kinne; Murray F. Brennan

• Publisher: John Wiley and Sons
• Year: 1987
• Tongue: English
• Weight: 496 KB
• Volume: 60
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(19871001)60:7<1620::aid-cncr2820600733>3.0.co;2-3

✦ Synopsis

Thirty-five women with breast cancer and primary hyperparathyroidism (I " H E ) were admitted to Memorial Hospital during a 25-year period. The incidence of primary hyperparathyroidism in the breast cancer patients was similar to the incidence in the total patient population at Memorial Sloan-Kettering Cancer Center (0.15% and 0.14%, respectively). The patients with 1 "HIT disease had clinical findings which distinguished them from those patients with cancer-related hypercalcemia. Eighty percent of the breast cancer patients with primary hyperparathyroidism had earlier stage disease (Stage 0, Stage 1, Stage 2); whereas 97% of the patients with breast cancer and hypercalcemia (not due to 1 "HIT) had advanced disease. There appeared to be a trend towards improved survival in the breast cancer patients with primary hyperparathyroidism when compared to patients of similar stage of disease who did not have parathyroid disease.